dc.contributor.author | Ioannidis, J. P. A. | en |
dc.contributor.author | Mauri, D. | en |
dc.contributor.author | Polyzos, N. P. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Ioannidis, J. P. A. | en |
dc.creator | Mauri, D. | en |
dc.creator | Polyzos, N. P. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:41Z | |
dc.date.available | 2018-06-22T09:53:41Z | |
dc.date.issued | 2007 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41969 | |
dc.language.iso | eng | en |
dc.source | Journal of the National Cancer Institute | en |
dc.subject | Tamoxifen | en |
dc.subject | Breast cancer | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Drug safety | en |
dc.subject | Overall survival | en |
dc.subject | Letter | en |
dc.subject | Aromatase inhibitor | en |
dc.subject | Cancer hormone therapy | en |
dc.subject | Exemestane | en |
dc.subject | Progression free survival | en |
dc.title | Response | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/jnci/djk023 | |
dc.description.volume | 99 | |
dc.description.issue | 2 | |
dc.description.startingpage | 176 | |
dc.description.endingpage | 177 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |